We are committed to researching and developing new, innovative,
disease-modifying solutions to address some of the most
difficult-to-treat neurologic diseases.
We are resolute in our commitment to help those living with and
affected by the realities of neurologic diseases. We strive to
preserve personhood in the face of unrelenting challenges. We stand
with patients, their families and healthcare providers to navigate
neuroscience’s unchartered frontiers and inevitable setbacks to
deliver science that will make a meaningful difference and a
remarkable impact on people’s lives.
Living with a Neurologic Disease
At AbbVie, we invest in neuroscience research that identifies opportunities to help people who live with neurologic disorders. We are advancing research and providing treatments across many neurologic disorders, including Alzheimer’s disease, bipolar disorder, bipolar depression, major depressive disorder, migraine, multiple sclerosis, Parkinson’s disease, post-stroke spasticity, schizophrenia, stroke and other central nervous system disorders.
We are committed to investing in research that identifies opportunities for real modification, delivering pioneering science, built on inevitable setbacks, that will make a meaningful difference for patients.
We have expanded our portfolio to include migraine to help those living with and affected by this debilitating disease, which affects one in seven people worldwide. We are committed to pursuing and providing treatment options that reduce the frequency and severity of headache and prevent migraine attacks.
On May 18, 2016, we opened a 43,000-square-foot Cambridge Research
Center in Cambridge, Massachusetts. At the Cambridge Research Center,
we undergo research to gain a deeper understanding of the biological
mechanisms underlying neurodegenerative diseases.
We are committed to helping those living with and affected by
neurologic diseases, including Alzheimer’s disease, bipolar disorder,
bipolar depression, major depressive disorder, migraine, multiple
sclerosis, Parkinson’s disease, post-stroke spasticity, and
schizophrenia.
We invest in research that identifies opportunities for real modification – delivering science that will make a meaningful difference in people’s lives.